Our research

Glioblastoma multiforme (GBM) is the most common and malignant brain tumor in adults. GBM is fatal 15 months after diagnosis with current therapies because of tumor recurrence and therapy resistance.

New forms of therapy are urgently needed.

We offer a new product as a novel therapy for treating GBM. Our product contains the antitumoral components and the environment modulators produced by a recently discovered human immune cell. 

Our intellectual property (IP) covers a faster way of detecting and producing the essential cells necessary for obtaining these components. Our product can double the life expectancy in preclinical models for GBM, hindering cell division similar to chemotherapy plus effectively modulating the tumor environment composition to boost the effect of immunotherapy.

Modulation of the tumor environment is a competitive advantage of our product compared to the current therapy, radiotherapy and chemotherapy. It allows immunotherapy and vaccine approaches to be efficient because the brain tumor tissue is prepared to respond and facilitate their effect, allowing patients to be sensitized to respond and extending the survival. 

Our novel therapy is based on research from Lund University in Sweden, repeatedly ranked among the world’s top 100 universities.